ArticleDermatology and therapy2026

AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks.

Edoardo Mortato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.